DOSE INTENSE MOPP FOR PATIENT WITH POOR PROGNOSIS HODGKINS DISEASE

该方案旨在治疗霍奇金病的子集， 治疗失败风险最高的患者。 较前一 在晚期霍奇金病的研究中，我们发现了患有 IIIB、IVB、IVA（骨髓）和巨大纵隔霍奇金病， 有较低的反应率和存活率。 为了提高 MOPP治疗在这组患者中的疗效， 所有药物均已增加，并给予GM-CSF以改善严重的 增加药物剂量的骨髓毒性作用。 到目前为止，24个中的22个 可评价的患者已达到完全缓解。 4名患者 旧病复发 一名诱导失败的患者此后接受了 同种异体骨髓移植，并取得了完全反应。 的 其他诱导失败者接受ABMT，达到CR，但在 两个月后死于疾病进展 4名患者 复发：1例ABMT后第二次CR，1例ABMT后复发 ABMT后短期CR;另外两人目前正在接受治疗。 24例可评价患者中有23例存活：21例无疾病，2例 何杰金氏病 未观察到非预期毒性， 这种待遇。

This protocol was designed to treat the subset of Hodgkin's disease patients who are at highest risk for treatment failure. From the previous study of advanced Hodgkin's disease, we have identified patients with Stage IIIB, IVB, IVA (marrow) and massive mediastinal Hodgkin's disease as having lower response rates and survival. In order to improve the efficacy of MOPP therapy in this group of patients, the dose-intensity of all drugs has been increased and GM-CSF is given to ameliorate the severe myelotoxic effects of the increased drug doses. To date, 22 of 24 evaluable patients have achieved a complete response. Four patients have relapsed. One patient who was an induction failure has since undergone an allogeneic bone marrow transplant and achieved a complete response. The other induction failure underwent ABMT, achieved a CR, but relapsed after two months and died with progressive disease. Four patients have relapsed: one is in second CR following ABMT, one has relapsed following a short CR after ABMT; two others are currently receiving therapy. Twenty-three of 24 evaluable patients are alive: 21 free of disease, two with Hodgkin's disease. No unexpected toxicities have been observed with this treatment.